Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Department of Oncology, Hematology & Bone Marrow Transplantation, University Medical Center of Hamburg-Eppendorf, Hamburg, 20246, Germany.
Future Oncol. 2021 Jun;17(16):1987-2003. doi: 10.2217/fon-2020-1269. Epub 2021 Mar 8.
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).
贝兰他单抗（belamaf）是一种 BCMA 靶向抗体药物偶联物，最近被批准用于治疗接受过≥4 种既往治疗的复发/难治性多发性骨髓瘤成人患者的单药治疗。Belamaf 与 BCMA 结合，并通过多种作用机制消除骨髓瘤细胞。贝兰他单抗的细胞毒性和潜在的免疫调节特性导致了与其他抗癌疗法的新联合研究。在这里，我们描述了 DREAMM-5 的原理和设计，这是一项正在进行的 I/II 期平台研究，评估 belamaf 联合新型药物（包括 GSK3174998（OX40 激动剂）、feladilimab（ICOS；GSK3359609）、nirogacestat（γ-分泌酶抑制剂；PF-03084014）和 dostarlimab（PD-1 阻断剂））与 belamaf 单药治疗复发/难治性多发性骨髓瘤患者的安全性和疗效。临床试验注册：NCT04126200（ClinicalTrials.gov）。
